search icon
  • Print
  • ShareThis
  • Text Size

February 25, 2016 COCA Call: Update on Interim Zika Virus Clinical Guidance and Recommendations

During this COCA Call, participants will learn why CDC has updated the clinical guidelines and how they can use the guidelines for Zika virus disease evaluation and testing.

For more information on this COCA Call visit:

Date: Thursday, February 25, 2016
Time: 2:00 - 3:00 pm (Eastern Time)

Join by Phone:
888-455-0056 (U.S. Callers)
517-308-9237 (International Callers)
Passcode: 7024369

Join by Webinar:
Link one:
Overflow link two:
Overflow link three:

New: FDA Recommendations to Reduce the Risk for Zika Virus Blood Transmission in the United States

In areas without active Zika virus transmission, the FDA recommends that donors at risk for Zika virus infection be deferred for four weeks. Individuals considered to be at risk include: those who have had symptoms suggestive of Zika virus infection during the past four weeks, those who have had sexual contact with a person who has traveled to, or resided in, an area with active Zika virus transmission during the prior three months, and those who have traveled to areas with active transmission of Zika virus during the past four weeks.

In areas with active Zika virus transmission, the FDA recommends that Whole Blood and blood components for transfusion be obtained from areas of the U.S. without active transmission. Blood establishments may continue collecting and preparing platelets and plasma if an FDA-approved, pathogen-reduction device is used. The guidance also recommends blood establishments update donor education materials with information about Zika virus signs and symptoms and ask potentially affected donors to refrain from giving blood.

Read more on FDA's website:

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site